BMS registers new deucravacitinib continuation study; prior week's trial results still stand

Bristol-Myers Squibb's registry activity this week centers on a new continuation study for deucravacitinib, alongside previously reported items that remain current.

• A new Phase 3 continuation protocol, sponsored by Bristol-Myers Squibb, will provide deucravacitinib to adult patients with systemic lupus erythematosus or Sjögren's Disease and pediatric patients with psoriasis or psoriatic arthritis who have completed their qualified parent studies and/or long-term extension if applicable.¹ The study is not yet recruiting, with an estimated start date of 2026-12-31¹, and enrollment is estimated at 2300 participants.¹
• A Phase 3 trial of subcutaneous versus intravenous nivolumab + relatlimab fixed-dose combination ("RELATIVITY-127") in previously untreated metastatic or unresectable melanoma posted results this week. The study, sponsored by Bristol-Myers Squibb, enrolled 579 participants² and compared serum drug exposure between the two formulations.
• A Phase 3 trial of nivolumab-relatlimab fixed-dose combination versus regorafenib or TAS-102 in later-line metastatic colorectal cancer ("RELATIVITY-123") also posted results this week. The Bristol-Myers Squibb-sponsored study enrolled 769 participants³ and had overall survival, defined as the time from date of randomization to the date of death due to any cause³, as its primary outcome; the trial's overall status is terminated.³
• An investigator-led Phase 2 trial testing neoadjuvant nivolumab and chemotherapy, with or without sub-ablative stereotactic body radiation therapy, in resectable Stage IIA to IIIB non-small cell lung cancer posted results this week. Montefiore Medical Center sponsors the study, with Bristol-Myers Squibb as a collaborator; the trial enrolled 17 participants⁴ and its primary objective is to compare the complete pathological response rate after 3 cycles of neoadjuvant nivolumab and platinum-based doublet chemotherapy vs. the same regimen with the addition of sub-ablative stereotactic radiation therapy (8 Gy x 3) directed at the primary lung tumor.⁴
• Bristol-Myers Squibb's observational registry study of long-term real-world safety of Cobenfy (xanomeline-trospium chloride) in adults with schizophrenia remains active not recruiting, with an estimated enrollment of 3000 participants.⁵ The study will evaluate the long-term real-world safety of xanomeline-trospium chloride in adults with schizophrenia receiving routine clinical care in the United States.⁵